XNAS · ALT
+3.86% · +$0.1200 · Vol Not reported
Pre-market · updated 05:00:44 ET
Altimmune, Inc. Common Stock

Altimmune, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$3.23
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
Earnings absence reason unknown
ALT
Altimmune, Inc. Common Stock
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ALT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ALT catalysts
About Altimmune, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2005
Employees
57
Country
US

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.11
Last session
Day high
$3.11
Last session
Day low
$3.11
Last session
Previous close
$3.11
52W high
$6.18
-47.73% from high
52W low
$2.59
18% of range
Market cap
$605M
EPS
$-0.7800
Beta
1.53
Shares out
194.5M
Avg volume
4.6M
VWAP
$3.11
Last session
Price history computed in-house
1W
+7.67%
1M
+16.61%
3M
+10.24%
1Y
-8.76%
YTD
-10.53%
SMA 50 $2.93 · above
SMA 200 $3.69 · below
52W position 18%

ALT overview

Veridion Score
59
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ALT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ALT Form 4 filings
Public disclosures

Congress activity in ALT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ALT in the cached public ledger.

Federal contracts

ALT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALT in this window.
Lobbying spend

ALT lobbying filings, year to date.

Registered lobbying filings matched to Altimmune, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALT in this window.
Loading news for ALT
Analyst ratings
Sovereign unlock shows live analyst consensus for ALT.
Options
Sovereign unlock shows live options positioning for ALT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.